Or­chard se­cures re­im­burse­ment for gene ther­a­py; UK fines drug­mak­ers $47M for an­ti­com­pet­i­tive scheme

Or­chard Ther­a­peu­tics an­nounced this week that the com­pa­ny has agreed to a re­im­burse­ment deal with Eng­land’s NHS for cov­er­age of its gene ther­a­py Lib­meldy.

Al­though Or­chard didn’t say how much NHS would pay for the ther­a­py, the deal is no­table be­cause of the dif­fi­cul­ties gene ther­a­py de­vel­op­ers have had com­ing to terms with pay­ers, even when the ther­a­pies have been ap­proved. In the most high-pro­file ex­am­ple, blue­bird bio pulled all of its gene ther­a­pies out of Eu­rope last year, say­ing coun­tries were not of­fer­ing a price com­men­su­rate with the val­ue of its drugs for two rare blood dis­or­ders and a rare neu­ro­log­i­cal con­di­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.